Abstract
Goserelin, a gonadotropin-releasing hormone agonist (GnRHa), has been widely used concurrently with chemotherapy to protect ovarian function for young breast cancer patients. However, potential negative interaction between the two treatments is a matter of concern due to few conclusive data on the oncological safety, especially for patients with positive hormone receptor. The aim of this study was to determine the impact of concurrent use of goserelin with neoadjuvant chemotherapy on pathological complete response (pCR).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
